You are here

Article Text

Article menu
Download PDFPDF
PostScript
Correspondence
Authors’ response to Young and Hopkins: vitamin D and lung function
  1. Shoaib Afzal1,2,
  2. Peter Lange2,3,4,5,
  3. Stig E Bojesen1,2,3,6,
  4. Jacob J Freiberg1,2,
  5. Børge G Nordestgaard1,2,3,6
  1. 1 The Department of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, Herlev, Denmark
  2. 2 The Copenhagen General Population Study, Herlev Hospital, Copenhagen University Hospital, Herlev, Denmark
  3. 3 The Copenhagen City Heart Study, Frederiksberg Hospital, Copenhagen University Hospital, Copenhagen, Denmark
  4. 4 Faculty of Health and Medical Sciences, Department of Public Health, Section of Social Medicine, University of Copenhagen, Herlev, Denmark
  5. 5 Section of Respiratory Medicine, Hvidovre Hospital, Copenhagen University Hospital, Herlev, Denmark
  6. 6 Faculty of Health and Medical Sciences, University of Copenhagen, Herlev, Denmark
  1. Correspondence to Professor Børge G Nordestgaard, Department of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, Herlev Ringvej 75, Herlev DK-2730, Denmark; Boerge.Nordestgaard{at}regionh.dk

https://doi.org/10.1136/thoraxjnl-2014-205133

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We thank Dr RP Young and Ms RJ Hopkins for their interest in our article and their constructive comments.1

    We agree with Dr RP Young and Ms RJ Hopkins that our analyses may suggest a threshold effect. However, we believe that more studies are needed before we firmly can assume a threshold effect. It is true that that the association between vitamin D level and FEV1% predicted was mirrored by a corresponding association between …

    View Full Text

    Footnotes

    • Contributors SA and BGN drafted the response, which was amended and finally approved by PL, SEB and JJF.

    • Competing interests PL received during the last 5 years pharmaceutical company grants from GSK in 2010 and 2011, Boehringer-Ingelheim and Almirall in 2012 via his home institution and also participated in speaking activities, industry advisory committee or other related activities sponsored by Almirall, Boehringer-Ingelheim, Novartis, GSK, AstraZeneca, Pfizer, Mundipharma and UCB during the period 2008–2012.

    • Provenance and peer review Not commissioned; internally peer reviewed.

    Linked Articles